全球慢性特發性便秘治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計慢性特發性便秘治療市場規模將從 2025 年的 38.9 億美元成長到 2034 年的 72.6 億美元，2026 年至 2034 年的複合年成長率為 7.17%。

由於胃腸道疾病盛行率不斷上升以及人們對現有治療方案的認知度不斷提高，慢性特發性便秘治療市場預計將迎來顯著成長。慢性特發性便秘（CIC）是一種常見疾病，其特徵是排便次數減少或排便困難，這會嚴重影響患者的生活品質。隨著醫療保健提供者尋求改善患者預後並更好地管理CIC，對瀉藥、處方藥和飲食療法等有效治療方法的需求預計將會增加，從而推動該市場的強勁成長。

此外，慢性特發性便秘（CIC）治療方法的進步正在推動市場創新。新型藥物的研發，例如鳥苷酸環化酶C促效劑和5-羥色胺受體促效劑，拓展了CIC的治療選擇，為患者提供更有效、更具針對性的治療方法。這些創新不僅改善腸道功能，還能解決便秘的潛在機制，進而提升患者的整體滿意度。隨著研究不斷探索新的治療方法和聯合治療，在改善患者照護和生活品質的推動下，慢性特發性便秘治療市場預計將進一步擴張。

此外，慢性特發性便秘的治療模式正在發生變化，越來越重視生活方式介入和預防性護理。隨著醫療保健提供者認知到飲食、水補充和體能活動在慢性特發性便秘管理中的重要性，對教育資源和支持計畫的需求預計將會增加。這種積極主動的方法不僅能幫助患者更好地管理自身病情，還能促進患者與醫療保健提供者之間的合作關係。隨著市場的不斷發展，結合創新治療方法、病患教育和生活方式介入的綜合方法將在推動未來成長方面發揮關鍵作用。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

4. 全球慢性特發性便秘治療市場（依類型分類）

• 市場分析、洞察與預測
• 正常傳輸型便秘
• 延遲性便秘
• 其他

5. 全球慢性特發性便秘治療市場（依治療方法）

• 市場分析、洞察與預測
• 藥物治療
• 非藥物療法

6. 全球慢性特發性便秘治療市場（依治療類型分類）

• 市場分析、洞察與預測
• 藥物
• 外科手術

7. 全球慢性特發性便秘治療藥物市場

• 市場分析、洞察與預測
• 血清素 4 (5-HT4) 受體促效劑
• 鳥苷酸環化酶C促效劑
• 瀉藥
• 刺激性瀉藥
• 其他

8. 全球慢性特發性便秘治療市場（依給藥途徑分類）

• 市場分析、洞察與預測
• 口服
• 注射

9. 全球慢性特發性便秘治療市場（以最終用戶分類）

• 市場分析、洞察與預測
• 醫院
• 居家照護
• 專科診所
• 其他

10. 全球慢性特發性便秘治療市場（依通路分類）

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第11章 全球慢性特發性便秘治療市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第12章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第13章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • ALLERGAN
  • Mallinckrodt Plc
  • Synergy Pharmaceuticals Inc
  • Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Shreya Life Sciences Pvt Ltd
  • Abbott
  • GSK Plc
  • Troikaa Pharmaceuticals Ltd
  • Lupin
  • East West Pharma
  • Ironwood Pharmaceuticals Inc

The Chronic Idiopathic Constipation Treatment Market size is expected to reach USD 7.26 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 7.17% during 2026-2034.

The chronic idiopathic constipation treatment market is poised for significant growth, driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of available treatment options. Chronic idiopathic constipation (CIC) is a common condition characterized by infrequent bowel movements and difficulty in passing stools, which can significantly impact patients' quality of life. As healthcare providers seek to improve patient outcomes and enhance the management of CIC, the demand for effective therapies, including laxatives, prescription medications, and dietary interventions, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in treatment options for CIC are driving innovation within the market. The development of novel pharmacological agents, such as guanylate cyclase-C agonists and serotonin receptor agonists, has expanded the therapeutic landscape for CIC, offering patients more effective and targeted treatment options. These innovations not only improve bowel function but also address the underlying mechanisms of constipation, enhancing overall patient satisfaction. As research continues to explore new therapies and combination treatments, the chronic idiopathic constipation treatment market is likely to expand further, driven by the promise of improved patient care and quality of life.

Additionally, the growing emphasis on lifestyle modifications and preventive care is shaping the chronic idiopathic constipation treatment landscape. As healthcare providers increasingly recognize the importance of diet, hydration, and physical activity in managing CIC, the demand for educational resources and support programs is likely to increase. This proactive approach not only empowers patients to take control of their condition but also fosters a collaborative relationship between patients and healthcare providers. As the market continues to evolve, the combination of innovative therapies, patient education, and a focus on lifestyle interventions will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Normal-transit constipation
• Slow-transit constipation
• Others

By Therapy Type

• Pharmacological Therapy
• Non-pharmacological Therapy
• ByA Treatment Type
• Medication
• Surgery

By Drugs

• Serotonin-4 (5-Ht4) Receptor Agonist
• Guanylate Cyclase-C Agonist
• Laxatives
• Stimulants
• Others

By Route of Administration

• Oral
• Injectable

By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others
• ByA Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• ALLERGAN, Mallinckrodt plc, Synergy Pharmaceuticals Inc, Shandong Luoxin Pharmaceutical Group Stock Co Ltd, Takeda Pharmaceutical Company Limited, Sanofi, Zydus Cadila, Boehringer Ingelheim International GmbH, Shreya Life Sciences Pvt Ltd, Abbott, GSK plc, Troikaa Pharmaceuticals Ltd, Lupin, East West Pharma, Ironwood Pharmaceuticals Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Normal-transit constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Slow-transit constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Type
• 5.2. Pharmacological Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-pharmacological Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Treatment Type
• 6.2. Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Drugs
• 7.2. Serotonin-4 (5-Ht4) Receptor Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Guanylate Cyclase-C Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Laxatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Stimulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY END-USERS 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End-users
• 9.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Distribution Channel
• 10.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 11.1. Regional Outlook
• 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.2.1 By Type
  • 11.2.2 By Therapy Type
  • 11.2.3 By Treatment Type
  • 11.2.4 By Drugs
  • 11.2.5 By Route Of Administration
  • 11.2.6 By End-users
  • 11.2.7 By Distribution Channel
  • 11.2.8 United States
  • 11.2.9 Canada
  • 11.2.10 Mexico
• 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.3.1 By Type
  • 11.3.2 By Therapy Type
  • 11.3.3 By Treatment Type
  • 11.3.4 By Drugs
  • 11.3.5 By Route Of Administration
  • 11.3.6 By End-users
  • 11.3.7 By Distribution Channel
  • 11.3.8 United Kingdom
  • 11.3.9 France
  • 11.3.10 Germany
  • 11.3.11 Italy
  • 11.3.12 Russia
  • 11.3.13 Rest Of Europe
• 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.4.1 By Type
  • 11.4.2 By Therapy Type
  • 11.4.3 By Treatment Type
  • 11.4.4 By Drugs
  • 11.4.5 By Route Of Administration
  • 11.4.6 By End-users
  • 11.4.7 By Distribution Channel
  • 11.4.8 India
  • 11.4.9 Japan
  • 11.4.10 South Korea
  • 11.4.11 Australia
  • 11.4.12 South East Asia
  • 11.4.13 Rest Of Asia Pacific
• 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.5.1 By Type
  • 11.5.2 By Therapy Type
  • 11.5.3 By Treatment Type
  • 11.5.4 By Drugs
  • 11.5.5 By Route Of Administration
  • 11.5.6 By End-users
  • 11.5.7 By Distribution Channel
  • 11.5.8 Brazil
  • 11.5.9 Argentina
  • 11.5.10 Peru
  • 11.5.11 Chile
  • 11.5.12 South East Asia
  • 11.5.13 Rest of Latin America
• 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.6.1 By Type
  • 11.6.2 By Therapy Type
  • 11.6.3 By Treatment Type
  • 11.6.4 By Drugs
  • 11.6.5 By Route Of Administration
  • 11.6.6 By End-users
  • 11.6.7 By Distribution Channel
  • 11.6.8 Saudi Arabia
  • 11.6.9 UAE
  • 11.6.10 Israel
  • 11.6.11 South Africa
  • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

• 12.1. Recent Developments
• 12.2. Company Categorization
• 12.3. Supply Chain & Channel Partners (based on availability)
• 12.4. Market Share & Positioning Analysis (based on availability)
• 12.5. Vendor Landscape (based on availability)
• 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Company Profiles
  • 13.2.1 ALLERGAN
  • 13.2.2 Mallinckrodt Plc
  • 13.2.3 Synergy Pharmaceuticals Inc
  • 13.2.4 Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • 13.2.5 Takeda Pharmaceutical Company Limited
  • 13.2.6 Sanofi
  • 13.2.7 Zydus Cadila
  • 13.2.8 Boehringer Ingelheim International GmbH
  • 13.2.9 Shreya Life Sciences Pvt Ltd
  • 13.2.10 Abbott
  • 13.2.11 GSK Plc
  • 13.2.12 Troikaa Pharmaceuticals Ltd
  • 13.2.13 Lupin
  • 13.2.14 East West Pharma
  • 13.2.15 Ironwood Pharmaceuticals Inc